Nodify XL2®
Lung Nodule Risk Assessment (Malignant vs. Benign)
CommercialFDA-cleared; Actively marketed
Key Facts
Indication
Lung Nodule Risk Assessment (Malignant vs. Benign)
Phase
Commercial
Status
FDA-cleared; Actively marketed
Company
About Biodesix
Biodesix is a data-driven diagnostic company that integrates proteomics, genomics, and artificial intelligence to deliver real-world diagnostic solutions for lung disease. The company has a commercial portfolio of blood-based tests, including the Nodify XL2® and Nodify CDT® tests for lung nodule management, and the GeneStrat® and VeriStrat® tests for therapy selection in NSCLC. Its strategy centers on expanding the clinical utility of its tests, driving adoption, and leveraging its proprietary Biodesix Lung Database® to develop new diagnostic products.
View full company profileTherapeutic Areas
Other Lung Nodule Risk Assessment (Malignant vs. Benign) Drugs
| Drug | Company | Phase |
|---|---|---|
| Nodify CDT® | Biodesix | Commercial |